Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11167998 | PMC |
| http://dx.doi.org/10.3760/cma.j.121090-20231012-00195 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
PICALM::MLLT10 fusion gene positive acute myeloid leukemia with PHF6 mutation and presented with CD7 positive immunophenotype.
Cytometry B Clin Cytom
November 2024
Department of Hematology, The Second Affiliated Hospital of Fujian Medical University, Quanzhou, China.
fusion gene in hematological neoplasms: clinical features, current practices, and prognoses.
Hematology
December 2024
Bone Marrow Transplantation Center of The First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, People's Republic of China.
Introduction: -, formerly , is a rarely reported fusion gene in hematological malignancies, especially in Asian people.
Case Presentations: Six patients with fusion gene were identified at the First Affiliated Hospital, Zhejiang University School of Medicine, China between October 2019 and October 2023, with a median age of 25 years. Clinical diagnoses included acute myeloid leukemia (AML) in 2 patients, acute lymphoblastic leukemia (ALL) in 3, and mixed phenotype acute leukemia (MPAL) in 1.
Clinicopathologic features and outcomes of acute leukemia harboring PICALM::MLLT10 fusion.
Hum Pathol
September 2024
Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, 55905, USA. Electronic address:
The PICALM::MLLT10 fusion is a rare but recurrent cytogenetic abnormality in acute leukemia, with limited clinicopathologic and outcome data available. Herein, we analyzed 156 acute leukemia patients with PICALM::MLLT10 fusion, including 12 patients from our institutions and 144 patients from the literature. The PICALM::MLLT10 fusion preferentially manifested in pediatric and young adult patients, with a median age of 24 years.
View Article and Find Full Text PDF[PICALM-MLLT10 fusion gene positive with multiple gene mutations in a child with T-lymphoblastic lymphoma/leukemia: a case report].
Zhonghua Xue Ye Xue Za Zhi
April 2024
Pediatric Hematology and Oncology Department, the Affiliated Hospital of Qingdao University, Qingdao 266000, China.
The fusion gene is a rare but recurrent event in acute leukemia (AL) associated with poor prognosis. It is still confused whether can solely correspond to acute myeloid leukemia (AML) or acute lymphoblastic leukemia (ALL) or acute leukemias of ambiguous lineage (ALAL). Here, we reported a series of positive AL patients with miscellaneous immunophenotype including T-ALL, ALAL, AML, and B-ALL, complex karyotype, half of extramedullary disease (EMD), frequently concomitant PHF6 mutation, and poor initial treatment response to standard chemotherapy aiming to different immunophenotype, but showing sensitivity to combining chemotherapy especially integrated with venetoclax, suggesting this fusion gene may indicate a new subgroup of AL.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!